TGFB1 and chronic obstructive pulmonary disease: If one or more of the PIs reach the stage of clinical trials, they have the potential to become a promising therapeutic strategy in the treatment of various pathologies characterised by dysregulated TGF‐β signalling, including fibrotic diseases, asthma, COPD and certain cancers, especially immune‐cold and immune‐excluded cancers.